Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of subcutaneous ropeginterferon alfa 2b ( P1101combined with
standard of care (SOC) compared with standard care alone in hospitalized adults with moderate
COVID 19.